Stony Brook (N.Y.) Heart Institute became the first center globally to administer a commercial dose of plozasiran, a newly approved RNA-interference therapy for familial chylomicronemia syndrome.
The Center for Advanced Lipid Management delivered the therapy within days of FDA approval, according to a Dec. 30 news release.
Plozasiran targets apolipoprotein C-III and, in phase 3 trials, significantly reduced triglyceride levels and pancreatitis episodes in patients with familial chylomicronemia syndrome, a rare genetic disorder that prevents the body from properly breaking down dietary fats. The syndrome affects an estimated 6,500 people in the U.S.
Leave a Reply